PROF. JAYANT S VAIDYA
I am Professor of Surgery and Oncology at University College London. Over the last 25 years, I have looked after over 2500 breast cancer patients.
I am considered a leading consultant surgeon, and oncology expert in diagnosis and treatment of all breast conditions. My special interest is in the treatment of breast cancer and am regularly invited for my expertise in the media and to government bodies such as NICE which decides on which treatments are made available on the NHS. I am the President-elect of British Association of Surgical Oncology~Association of Cancer Surgeons (BASO~ACS) and the London Representative of Association of Breast Surgeons (ABS).
I have over 200 original scholarly publications in a wide range of medical fields. My main research aim over the past twenty-five years has been to improve our understanding and treatment of breast cancer. Progressive thinking and research has led to changes in the way breast cancer is treated today.
TARGIT-IORT for breast cancer
My work on Intraoperative Radiotherapy (IORT) was inspired by original laboratory work in 1994-5, leading to the idea that breast cancer treatment with surgery and radiotherapy needs to be focussed and targeted. Working with Professor Michael Baum and Professor Jeffrey S Tobias, in UCL, London, I developed the concept, tools (Intrabeam) and the surgical operative procedure (TARGIT IORT) to give targeted intraoperative radiotherapy to the tissues immediately around a breast cancer, after it is surgically removed (lumpectomy). I named this technique TARGIT- for TARGeted Intraoperative radioTherapy and it is commonly called Intrabeam TARGIT IORT. The Intrabeam TARGIT IORT procedure has been now been used to treat in over 40,000 breast cancer patients worldwide. This research was included the list of Best Cancer Breakthroughs list
MY LATEST RESEARCH
The Intrabeam TARGIT IORT procedure has been now been used to treat in over 35,000 breast cancer patients in 280 centres in 38 countries worldwide. I would encourage the interested reader to visit the Intrabeam TARGIT IORT webpages giving the details of TARGIT-A trial. The UK (NICE) recommended TARGIT IORT for suitable breast cancer patients https://www.ucl.ac.uk/news/2018/feb/nhs-breast-cancer-patients-benefit-go-ahead-ucl-pioneered-treatment
Single-dose TARGIT IORT given during lumpectomy achieves breast cancer control similar to whole breast radiotherapy given daily over several weeks. In addition restricting the radiation to only the tissues at risk means avoiding unnecessary radiation to vital organs. This video shows how partial breast irradiation improved survival.